17 [1.73–5.82] 0.15 Nausea/vomiting 56 115.7/3,159.5 [3.7] 92.7/2,995.5 [3.1] 1.22 [0.92–1.61] 0.36 Abdominal pain 20 40.7/1,342 [3.0] 19.8/1,233 [1.6] 1.92 [1.12–3.27] 0.47 Aspirin SIS3 order vs. NSAIDs/analgesics Gastrointestinal events 5 565/3,105 [18.2] 737/6,037 [12.2] 1.61 [1.43–1.82] 0.02 Minor gastrointestinal events 50 609.1/4,888 [12.5]
736.8/9,471 [7.8] 1.81 [1.61–2.04] 0.19 selleck chemical dyspepsia 26 233.9/3,889 [6.0] 258.3/7,427 [3.5] 1.94 [1.61–2.35] 0.43 Nausea/vomiting 43 206.5/4,693 [4.4] 320.4/9,229 [3.5] 1.37 [1.14–1.64] 0.17 Abdominal pain 20 369.6/3,755 [9.8] 406.9/7,332 [5.6] 1.95 [1.68–2.27] 0.42 Aspirin vs. ibuprofen Gastrointestinal events 1 534/2,890 [18.5] 330/2,869 [11.5] 1.74 [1.50–2.02] SNX-5422 concentration ND Minor gastrointestinal events 13 493.7/3,238 [15.2] 288.1/3,430 [8.4] 2.02 [1.73–2.37] 0.19 Dyspepsia 10 193.5/3,129 [6.2] 100.8/3,320 [3.0] 2.27 [1.76–2.93] 0.73 Nausea/vomiting 11 145.5/3,177 [4.6] 111.1/3,335 [3.3] 1.45 [1.13–1.87]
0.08 Abdominal pain 6 332.9/3,015 [11.0] 183.7/3,026 [6.1] 2.00 [1.65–2.42] 0.34 Aspirin vs. naproxen Gastrointestinal events 0 ND ND ND ND Minor gastrointestinal events 6 18.8/187 [10.1] 5.4/211 [2.6] 5.36 [1.95–14.7] 0.15 Dyspepsia 5 9.3/157 [5.9] 4.4/181 [2.4] 3.40 [1.03–11.2] 0.72 Nausea/vomiting 5
8.9/140 [6.3] 1/166 [0.6] 8.84 [1.54–50.8] 0.04 Abdominal pain 4 9.4/151 [6.2] 0/174 [0.0] 68.9 [0.93–5,100] 0.97 Aspirin vs. diclofenac Gastrointestinal events 1 5/54 [9.3] 5/109 [4.6] 2.12 [0.59–7.67] Cediranib (AZD2171) ND Minor gastrointestinal events 4 6.3/166 [3.8] 6.8/370 [1.8] 1.31 [0.39–4.46] 0.27 Dyspepsia 1 1/6 [16.7] 2.4/7 [34.3] 0.38 [0.03–5.45] ND Nausea/vomiting 3 1/106 [0.9] 4/310 [1.3] 0.43 [0.04–4.95] 0.66 Abdominal pain 1 5/60 [8.3] 1/60 [1.7] 5.36 [0.61–47.4] ND CI confidence interval, ND no data, NSAID nonsteroidal anti-inflammatory drug, OR odds ratio a P value for heterogeneity In 59 studies with 3,304.5 subjects receiving aspirin and 3,170.5 subjects receiving placebo, 5.2 % of aspirin subjects reported a minor gastrointestinal complaint (abdominal pain, dyspepsia, or nausea/vomiting), versus 3.7 % of placebo subjects. The corresponding summary OR was 1.46 (95 % CI 1.15–1.86) [see Table 2 and see Appendix 3 in the Electronic Supplementary Material]. The ORs for dyspepsia (3.17, 95 % CI 1.73–5.82) and abdominal pain (1.92, 95 % CI 1.12–3.27) were also increased significantly. Similar findings emerged in comparisons of aspirin with any active comparator (50 studies with 4,888 and 9,471 subjects, respectively). The pooled risks of minor gastrointestinal complaints were 12.